Micreos is a platform biotech company focused on discovering and developing recombinant proteins for chronic dermatological disease
Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions that selectively kill only harmful bacteria while preserving the rest of the health-enhancing microbiome.
Our vision is to positively impact patient care while helping global health care systems to address impending anti-microbial resistance (AMR) concerns.
Our unique capability in modular engineering to optimize enzyme therapeutics means that we have already developed three endolysin-based investigational antimicrobials.
These antimicrobials are focused on the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology and bloodstream infections.
Our team is forging ahead, partnering across medicine, to realize the shared goal of better solutions to combat harmful bacteria in an era of antimicrobial resistance.
Welcome to Micreos.
Beyond resistance
Company Details
- Employees
- 16
- Founded
- -
- Address
- Neuhofstrasse 12, Baar,zug 6340,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.micreos.com
- Keywords
- London.
- HQ
- Baar, Zug
Micreos Questions
Micreos's website is http://www.micreos.com
Micreos's LinkedIn profile is https://ch.linkedin.com/company/micreos-ag
Micreos has
16 employees.
View email and phone details for 16
employees at Micreos.
Micreos's industry is
Biotechnology Research
Micreos's top competitors are
Ucea - Family Office Group,
Gladskin,
Portal Instruments,
Metch,
Northway Biotech,
Intralytix, Inc.,
Novosere,
Micreos Group,
Phagelab,
Phageguard.
Micreos's categories are Biotechnology Research
Micreos's founding year is 2022
